# William Pao

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/william-pao/

## Facts

| Field | Value |
| --- | --- |
| Citations | 67,108 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 113 |
| i10-index | 229 |
| Last Known Institution | Vanderbilt University |
| OpenAlex ID | https://openalex.org/A5062616992 |
| Works | 667 |

## Researcher papers

Showing 12 of 16.

- [EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib](https://scholariq.org/papers/egf-receptor-gene-mutations-are-common-in-lung-cancers-from-never-smokers-and/)
- [Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain](https://scholariq.org/papers/acquired-resistance-of-lung-adenocarcinomas-to-gefitinib-or-erlotinib-is/)
- [Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers](https://scholariq.org/papers/analysis-of-tumor-specimens-at-the-time-of-acquired-resistance-to-egfr-tki/)
- [Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing](https://scholariq.org/papers/mapping-the-hallmarks-of-lung-adenocarcinoma-with-massively-parallel-sequencing/)
- [Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs](https://scholariq.org/papers/using-multiplexed-assays-of-oncogenic-drivers-in-lung-cancers-to-select-targeted/)
- [<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib](https://scholariq.org/papers/i-met-i-amplification-occurs-with-or-without-i-t790m-i-mutations-in-i-egfr-i/)
- [<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers](https://scholariq.org/papers/i-ros1-i-rearrangements-define-a-unique-molecular-class-of-lung-cancers/)
- [KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib](https://scholariq.org/papers/kras-mutations-and-primary-resistance-of-lung-adenocarcinomas-to-gefitinib-or/)
- [Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer](https://scholariq.org/papers/integrative-genome-analyses-identify-key-somatic-driver-mutations-of-small-cell/)
- [New driver mutations in non-small-cell lung cancer](https://scholariq.org/papers/new-driver-mutations-in-non-small-cell-lung-cancer/)
- [Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation](https://scholariq.org/papers/acquired-resistance-to-egfr-tyrosine-kinase-inhibitors-in-egfr-mutant-lung/)
- [<i>RET</i> Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/i-ret-i-fusions-define-a-unique-molecular-and-clinicopathologic-subtype-of-non/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Vanderbilt University](https://scholariq.org/institutions/vanderbilt-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.